New malaria vaccine combo shows promise in early trial
NCT ID NCT06507605
First seen Jan 20, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tested a new malaria vaccine combination (Pfs230D1 and R21 with Matrix-M) in 240 healthy African adults aged 18-50. The goal was to check safety and immune response. The vaccine aims to prevent both malaria infection and transmission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF MALARIA TRANSMISSION AND CLINICAL MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Science, Technique and Technology of Bamako (Usttb)
Bamako, Mali
Conditions
Explore the condition pages connected to this study.